THOMAS JAMES DOYLE - 13 Nov 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role: SVP, Finance & Accounting
Signature: Teresa Bair, Attorney-in-fact for Thomas Doyle
Issuer symbol: KURA
Transactions as of: 13 Nov 2025
Net transactions value: -$50,732
Form type: 4
Filing time: 14 Nov 2025, 20:00:05 UTC
Previous filing: 29 Sep 2025
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
DOYLE THOMAS JAMES	SVP, Finance & Accounting	C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO	Teresa Bair, Attorney-in-fact for Thomas Doyle	14 Nov 2025	0001910331

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KURA	Common Stock	Award	$0	+24,967	+23%	$0.000000	134,796	13 Nov 2025	Direct
transaction	KURA	Common Stock	Sale	$50,732	-4,539	-3.4%	$11.18	130,257	14 Nov 2025	Direct	F1
holding	KURA	Common Stock						500	13 Nov 2025	spouse's 401(k)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.

Content

Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.